Clinical Trial: A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15Same as current

Current Secondary Outcome: changes in Mini-Mental State Examination (MMSE [ Time Frame: 16 weeks ]

The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score of 30, with higher scores indicating better function. MMSE shall be recorded at the start and end of study provided it is a part of routine clinical practic


Original Secondary Outcome: Same as current

Information By: Novartis

Dates:
Date Received: December 8, 2016
Date Started: May 31, 2017
Date Completion: August 31, 2018
Last Updated: February 19, 2017
Last Verified: February 2017